Valuation: Orthocell Limited

Market Cap 21Cr 14Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 144.92Cr 56Cr 707.15Cr 54Cr 53Cr 2.27TCr P/E 2027 *
-15.3x
P/E 2028 * -38.3x
Enterprise Value 18Cr 12Cr 11Cr 10Cr 9.45Cr 18Cr 1.2TCr 125.44Cr 49Cr 612.11Cr 47Cr 46Cr 1.97TCr EV / Sales 2027 *
9.49x
EV / Sales 2028 * 4.83x
Free-Float
83.41%
Yield 2027 *
-
Yield 2028 * -
1 week-0.65%
3 months+5.52%
6 months-4.38%
Current year-29.49%
1 week 0.74
Extreme 0.735
0.8
1 month 0.67
Extreme 0.67
0.8
Current year 0.67
Extreme 0.67
1.16
1 year 0.67
Extreme 0.67
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
20/07/26 Buy

Chairman

15,430 0.0057%
17/07/26 Buy 11,573 0.0043%
17/07/26 Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.65%-45.94%+104.00% 14Cr
-2.15%-2.65%+24.44%+33.20% 25TCr
-3.13%-4.21%+0.69%+0.29% 16TCr
-0.96%+0.68%-8.18%+36.36% 14TCr
-0.46%-2.83%-54.71%-17.79% 6.33TCr
-1.15%-0.58%+11.69%+23.20% 4.98TCr
-1.96%-2.41%+21.72%+52.10% 4.86TCr
-0.95%+1.07%-18.77%-21.76% 4.8TCr
-0.47%+3.35%-3.14%+41.19% 4.62TCr
-1.64%+0.05%+34.61%+59.14% 4.32TCr
Average -1.27%+1.98%-3.76%+30.99% 8.48TCr
Weighted average by Cap. -1.71%+2.37%+4.30%+23.04%

Financials

2027 *2028 *
Net sales 1.9Cr 1.32Cr 1.17Cr 1.09Cr 99.55L 1.87Cr 126.63Cr 13Cr 5.12Cr 64Cr 4.94Cr 4.83Cr 207.14Cr 3.8Cr 2.63Cr 2.34Cr 2.18Cr 1.99Cr 3.75Cr 253.26Cr 26Cr 10Cr 128.98Cr 9.88Cr 9.66Cr 414.29Cr
Net income -1.3Cr -89.99L -79.93L -74.75L -68.12L -1.28Cr -87Cr -9.04Cr -3.5Cr -44Cr -3.38Cr -3.31Cr -141.73Cr -52.5L -36.34L -32.28L -30.19L -27.51L -51.79L -35Cr -3.65Cr -1.41Cr -18Cr -1.36Cr -1.33Cr -57Cr
Net Debt -2.8Cr -1.94Cr -1.72Cr -1.61Cr -1.47Cr -2.76Cr -186.62Cr -19Cr -7.54Cr -95Cr -7.28Cr -7.12Cr -305.26Cr -2.46Cr -1.71Cr -1.52Cr -1.42Cr -1.29Cr -2.43Cr -164.29Cr -17Cr -6.64Cr -84Cr -6.41Cr -6.27Cr -268.74Cr
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
01/26/01 A$0.7650 0.00% 3,08,384
30/26/30 A$0.7650 +2.68% 3,09,226
29/26/29 A$0.7450 0.00% 31,816
28/26/28 A$0.7450 +0.68% 3,87,715
25/26/25 A$0.7400 -5.13% 3,47,259
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7650AUD
Average target price
1.140AUD
Spread / Average Target
+49.02%

Quarterly revenue - Rate of surprise